Prof. Lin Wu 邬麟
Chief Physician, Professor
Department of Medical Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Personalized precision medicine and molecular targeted therapy for lung cancer, esophageal cancer, mediastinal tumors, and pleural malignancies. Focuses on standardized diagnosis and treatment, and clinical trials of new anti-tumor drugs.
Dr. Lin Wu is Director of the Second Department of Thoracic Internal Medicine at Hunan Cancer Hospital. Holding a doctorate in internal medicine, Dr. Wu serves as a doctoral supervisor at Central South University. With extensive experience in medical oncology, Dr. Wu specializes in chemotherapy and targeted therapy for thoracic tumors. As a visiting scholar at Regina Elena National Cancer Institute in Italy and the University of Minnesota in the US, Dr. Wu leads over 40 multi-center clinical trials.
Professional roles
- Standing Committee Member and Vice Chair of the Lung Cancer Professional Committee, China South Oncology Clinical Research Association (CSWOG)
- Member of the Medical Oncology Group, Oncology Branch, Chinese Medical Association
- Standing Committee Member, Young Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Chair, Clinical Tumor Chemotherapy Professional Committee, Hunan Anti-Cancer Association
Name order: in Chinese the family name comes first (Wu Lin). Papers usually list the name as Lin Wu or Wu L.
Selected publications
218 papers on PubMed matched by name and affiliation; 34 as first or senior author since 2016. Most recent first- or senior-author papers:
- Expert Opin Biol Ther, 2026 (senior author): An evaluation of sacituzumab tirumotecan for the treatment of NSCLC. PubMed 42888178
- Cancer Immunol Immunother, 2026 (senior author): Real-world evidence of immunotherapy in older adults with advanced non-small cell lung cancer: a retrospective cohort study. PubMed 42980858
- BMC Med, 2026 (first author): Real-world serplulimab plus chemotherapy for extensive-stage small cell lung cancer in china: an external validation of ASTRUM-005 trial. PubMed 42458439
- Lung Cancer, 2026 (senior author): Immunotherapy rechallenge in Extensive-Stage small cell lung Cancer: A Real-World retrospective study. PubMed 41825179
- Lung Cancer, 2026 (first author): Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study. PubMed 41365111
- Zhongguo Fei Ai Za Zhi, 2025 (senior author): [Combination of Radiotherapy and Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer: Clinical Progress Advances and Future Directions]. PubMed 41622934
- Zhongguo Fei Ai Za Zhi, 2025 (senior author): [Clinical Progress and Prospects of Antibody-drug Conjugates in Advanced NSCLC]. PubMed 41158043
- Thorac Cancer, 2025 (senior author): Immune Checkpoint Inhibitor-Based Therapy as the First-Line Treatment for Advanced Non-Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives. PubMed 40551477
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion